Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, Aceh, Indonesia.
Department of Parasitology, Faculty of Veterinary Medicine, Universitas Syiah Kuala, Banda Aceh, Aceh, Indonesia.
Vasc Health Risk Manag. 2023 Mar 12;19:139-144. doi: 10.2147/VHRM.S401521. eCollection 2023.
Ascorbic acid and calcitriol were frequently utilized in conjunction as therapy during the COVID-19 pandemic, and individuals with minor symptoms had notable improvements. There have been a few studies, often with conflicting findings, that examine the use of them for endothelium restoration and numerous clinical trial studies that failed to establish the efficacy. The aim of this study was to find the efficacy of ascorbic acid compared to calcitriol on the inflammatory markers monocyte chemoattractant protein-1 (MCP-1), nitric oxide (NO), and superoxide dismutase (SOD), as protective agents which play an important role in the early stages of atherosclerosis formation. This study was an experimental in vivo study.
The total of 24 male strain Wistar rats were divided into 4 groups, namely: control/normal group (N), atherosclerosis group (DL) given atherogenic diet, atherosclerosis group given atherogenic diet and ascorbic acid (DLC), and atherosclerosis group given atherogenic diet and calcitriol (DLD) treatment for 30 days.
Ascorbic acid and calcitriol treatment was significantly effective (<0.05) in lowering expression of MCP-1 and increasing NO and SOD level. Calcitriol was superior to ascorbic acid in increasing SOD (<0.05). There was no significant difference between ascorbic acid and calcitriol in decreasing MCP-1 and increasing NO (>0.05).
Both treatments could reduce MCP-1, and increase NO and SOD by increasing antioxidants. In this study calcitriol was superior to ascorbic acid in increasing SOD, but not NO and decreasing MCP-1. According to the theory, it was found that calcitriol through nuclear factor erythroid 2-related factor 2 (Nrf2) causes a direct increase in the amount of SOD. Nrf2 is an emerging regulator of cellular resistance to oxidants.
Ascorbic acid and calcitriol treatment was able to reduce MCP-1 and increase NO and SOD in atherosclerosis rat. Calcitriol was significantly superior in increasing SOD levels compared to ascorbic acid.
在 COVID-19 大流行期间，抗坏血酸和骨化三醇经常联合用作治疗药物，轻症患者的症状有明显改善。有一些研究，结果往往相互矛盾，研究了它们对内皮细胞修复的作用，还有许多临床试验未能确定其疗效。本研究旨在比较抗坏血酸和骨化三醇对单核细胞趋化蛋白-1（MCP-1）、一氧化氮（NO）和超氧化物歧化酶（SOD）等炎症标志物的疗效，这些标志物在动脉粥样硬化形成的早期阶段发挥重要作用。本研究为体内实验研究。
将 24 只雄性 Wistar 大鼠随机分为 4 组，即：正常对照组（N）、给予致动脉粥样硬化饮食的动脉粥样硬化组（DL）、给予致动脉粥样硬化饮食和抗坏血酸的动脉粥样硬化组（DLC）和给予致动脉粥样硬化饮食和骨化三醇的动脉粥样硬化组（DLD），治疗 30 天。
抗坏血酸和骨化三醇治疗可显著降低 MCP-1 表达，增加 NO 和 SOD 水平（<0.05）。与抗坏血酸相比，骨化三醇增加 SOD 的效果更好（<0.05）。抗坏血酸和骨化三醇在降低 MCP-1 和增加 NO 方面无显著差异（>0.05）。
两种治疗方法均可通过增加抗氧化剂来降低 MCP-1，增加 NO 和 SOD。在本研究中，骨化三醇在增加 SOD 方面优于抗坏血酸，但在增加 NO 和降低 MCP-1 方面无差异。根据理论，发现骨化三醇通过核因子红细胞 2 相关因子 2（Nrf2）直接增加 SOD 的量。Nrf2 是一种新兴的细胞抗氧化剂抵抗调节剂。
抗坏血酸和骨化三醇治疗可降低动脉粥样硬化大鼠的 MCP-1 并增加 NO 和 SOD。与抗坏血酸相比，骨化三醇可显著增加 SOD 水平。
